Connect your AI

Vivani Medical VANI Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

MBX Biosciences, Inc.MBX

$378K—

Other financials

Income statement

Revenue-—

Gross profit$130.0K—

Operating income-$6.8M-4.0%

Net income-$6.8M-7.6%

EPS (diluted)-$0.08+27.3%

Balance sheet

Cash & equivalents$19.0M+57.7%

Total debt$18.3M-3.5%

Total equity$19.1M+64.2%

Total assets$42.4M+19.5%

Cash flow

Operating cash flow-$6.2M-20.0%

CapEx$3.0K-40.0%

Free cash flow-$6.2M-19.9%

Valuation

Market cap$106.93M+40.0%

Enterprise value$106.17M+19.3%

Profitability

Gross margin36.3%—

Operating margin-1,004.9%—

Net margin-994.1%—

FCF margin-832.3%—

Returns & leverage

Return on equity-176.4%+175pp

Debt / equity1×-0.7×

Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vivani Medical's payments of stock issuance costs?: Vivani Medical (VANI) reported payments of stock issuance costs of $28K in Q1 2025.